Therapeutic antitumor activity generated by A20/αGC vaccination. (A,B) BALB/c mice were inoculated with 1 × 10⁶ live A20 cells intravenously at day 0. On day 5 (day +5) or day 10 (day +10), mice were vaccinated with A20/veh, A20/αGC, or left untreated (Nil) (n=7-10 per group), and the survival was monitored. (C) Survivors from panel A were rechallenged with live A20 cells 80 days after primary tumor inoculation, and the survival was monitored. Age-matched naive mice were used as control (Nil; n=5). P values were calculated in comparison with the nonvaccinated group.